EXHIBIT 99.1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter) |
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
| ||
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code (
______________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Warrants to Purchase Common Stock |
| LEXXW |
| The The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 | Regulation FD |
On April 19, 2022, Lexaria Bioscience Corp. (“Lexaria”) was advised that an update (the “Update”) to the original investor report published by Zacks Investment Research, Inc. (“Zacks”) on September 20, 2021 and previously updated on December 16, 2021 and February 2, 2022 (the “Report”) had been published and disseminated via institutional investor platforms, retail investor platforms, social media and directly to Zack’s subscribers.
Lexaria paid Zacks US$39,000 to provide annual analyst coverage which includes the preparation of four Updates to the Report. The Update contains certain future projections for Lexaria’s revenues for the 2022, 2023 and 2024 fiscal years as well as valuations. A full copy of the Update is attached hereto as Exhibit 99.1.
Item 9.01 | Financial Statements and Exhibits |
|
|
- 2 - |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP. |
| |
|
| |
/s/ Chris Bunka |
| |
Chris Bunka |
| |
CEO, Principal Executive Officer |
| |
|
| |
Date: | April 20, 2022 |
|
- 3 - |
EXHIBIT 99.1